Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Rheum Dis. 2008 Dec;67(12):1736-8. doi: 10.1136/ard.2008.094516. Epub 2008 Aug 19.

Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.

Author information

  • 1Département de Rhumatologie, AP-HP Hôpital Cochin, University Paris-Descartes, Paris 75014, France. christian.roux@cch.aphp.fr

Abstract

OBJECTIVES:

Early osteoporotic fractures have a great impact on disease progression, the first fracture being a major risk factor for further fractures. Strontium ranelate efficacy against vertebral fractures is presently assessed in a subset of women aged 50-65 years.

METHODS:

The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international, double blind, placebo controlled trial, supporting the efficacy of strontium ranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. 353 of these randomly assigned women were included in this analysis.

RESULTS:

Over 4 years, strontium ranelate significantly reduced the risk of vertebral fracture by 35% (relative risk 0.65; 95% CI 0.42 to 0.99, p<0.05). In the strontium ranelate group, the bone mineral density increased from baseline by 15.8% at lumbar spine and 7.1% at femoral neck.

CONCLUSION:

These data demonstrate a significant vertebral antifracture efficacy of strontium ranelate in young postmenopausal women aged 50-65 years with severe osteoporosis and confirm the efficacy of this antiosteoporotic treatment to prevent vertebral fractures, whatever the age of the patient.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk